RxDoctor Payments Data

Vijay Samuel, MD

Neurology · Novi, MINPI 1285787739

Payments from drug & device makers

$111,084in general payments, 2019–2025

Across 1,914 payments — averaging $58.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • EMD Serono, Inc.$30K
  • Sanofi$17K
  • Biogen$16K
  • Novartis$9K
  • Teva Pharmaceuticals USA, Inc.$7K
  • AbbVie$5K
  • plus $27K from 54 others

What the payments were for

  • Consulting fees$20,76419%
  • Speaking & faculty fees$45,52442%
  • Travel & lodging$6,6186%
  • Food & beverage$34,44332%
  • Education$2340%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
EMD Serono, Inc.129$29,822
Sanofi77$17,004
Biogen122$15,780
Novartis295$9,113
Teva Pharmaceuticals USA, Inc.79$6,865
AbbVie(2 entities)130$5,376
Catalyst Pharmaceuticals, Inc.7$3,639
UCB, Inc.186$3,213
MDD US Operations, LLC18$2,565
TG Therapeutics, Inc.41$1,522
Bristol Myers Squibb100$1,354
Amgen(2 entities)51$1,176
Genentech USA, Inc.58$1,113
Jazz Pharmaceuticals Inc.10$1,041
Lilly USA, LLC60$980
Neurocrine Biosciences, Inc.38$883
Eisai Inc.32$738
Alnylam Pharmaceuticals Inc.39$605
Neurelis, Inc.26$524
Pfizer36$524
Acorda Therapeutics, Inc32$474
AstraZeneca(2 entities)22$459
SK Life Science, Inc.21$454
Lundbeck LLC19$409
Avanir Pharmaceuticals, Inc.27$386
Supernus Pharmaceuticals, Inc.36$383
E.r. Squibb & Sons, L.L.C.8$383
Sunovion Pharmaceuticals Inc.19$289
Biohaven Pharmaceutical Holding Company Ltd.10$287
Takeda Pharmaceuticals U.S.A., Inc.10$239
Mallinckrodt Hospital Products Inc.10$238
Argenx US, Inc.7$212
CSL Behring10$204
Biohaven Pharmaceuticals, Inc.7$203
Sumitomo Pharma America, Inc.14$167
Harmony Biosciences LLC7$155
Tanabe Pharma America, Inc.7$153
Kyowa Kirin, Inc.7$120
Johnson & Johnson3$120
Corium, LLC6$119
Aucta Pharmaceuticals, Inc.10$116
Ipsen Biopharmaceuticals, Inc6$112
Otsuka America Pharmaceutical, Inc.6$111
Livanova USA, Inc.5$109
Assertio Therapeutics, Inc.6$102
Greenwich Biosciences, Inc.4$95
Vanda Pharmaceuticals Inc.3$91
Axsome Therapeutics, Inc.4$82
Adamas Pharmaceuticals, Inc.4$76
Acadia Pharmaceuticals Inc4$72
Banner Life Sciences, LLC3$70
Currax Pharmaceuticals LLC4$61
Amneal Pharmaceuticals LLC2$60
Hospira, Inc.4$58
Grifols USA, LLC3$51
Idorsia Pharmaceuticals US Inc2$45
Upsher-smith Laboratories LLC3$38
Endo Pharmaceuticals Inc.2$37
Scilex Pharmaceuticals Inc.2$37
Impel Pharmaceuticals Inc.2$35

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$111,084 in reported general payments places this provider in the 85th percentile of 652 neurology providers in Michigan.

See all neurology providers in Michigan

Medicare billing

Part B allowed, 2024
$63,917
Medicare patients
214
Services billed
518

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab52$578,386
CopaxoneGlatiramer Acetate67$427,775
Avonex Pen (4 Pack)Interferon Beta-1a52$390,086
WakixPitolisant Hcl11$150,814
BriviactBrivaracetam34$60,868
UbrelvyUbrogepant29$55,213
Dalfampridine ErDalfampridine47$55,137
Glatiramer Acetate26$49,940
NeuproRotigotine21$23,930
AptiomEslicarbazepine Acetate14$22,430
NuedextaDextromethorphan Hbr/Quinidine15$14,494
Topiramate171$10,129
Aimovig AutoinjectorErenumab-Aooe11$9,179
Gabapentin414$8,158
Rasagiline Mesylate43$7,302

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Copaxone$6,865$427,77567 claims
Harmony Biosciences LLCWakix$155$150,81411 claims
UCB, Inc.Briviact, Neupro$3,213$84,79855 claims
AbbVieUbrelvy$5,376$55,21329 claims
Sunovion Pharmaceuticals Inc.Aptiom$289$22,43014 claims
Avanir Pharmaceuticals, Inc.Nuedexta$386$14,49415 claims
Upsher-smith Laboratories LLCTopiramate$38$10,129171 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 652 neurology providers in Michigan.

Other neurology in Novi

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →